Suggested remit: To appraise the clinical and cost effectiveness of atogepant within its marketing authorisation for preventing migraine.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information DHSC referral received
Process TA
ID number 5090

Provisional Schedule

Final draft guidance 11 April 2024 - 25 April 2024
Expected publication 15 May 2024

Project Team

Project lead Celia Mayers

Email enquiries

External Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Companies sponsors AbbVie (atogepant)
Others Department of Health and Social Care
  NHS England
Patient carer groups Migraine Trust
Professional groups Association of British Neurologists
  British Pain Society
  Royal College of Physicians
  UK Clinical Pharmacy Association
Comparator companies AbbVie (botulinum toxin type A)
  Eli Lilly (galcanezumab)
  Lundbeck (eptinezumab)
  Novartis (erenumab)
  Pfizer (rimegepant)
  Teva UK (fremanezumab)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups National Institute for Health Research


Key events during the development of the guidance:

Date Update
08 February 2024 Committee meeting
05 October 2023 This topic will continue as a single technology appraisal (STA) rather than a cost comparison appraisal. The company, AbbVie, will be submitting evidence in late September 2023. The first committee meeting will be held on 8 February 2024.
18 January 2023 Invitation to participate
18 January 2023 We have selected atogepant for preventing migraine for a pilot for the proportional approach to technology appraisals sub process: a streamlined approach to Cost Comparison Appraisals. We believe efficiencies can be made to the current cost comparison approach which would result in a faster route to a recommendation for companies, quicker access for patients and a less resource intensive process for all involved. There will be a shorter submission period and external assessment group (EAG) review of the company’s evidence submission. In late April 2023, NICE will advise a subset of the committee (the chair and vice chair) of the appropriateness of cost comparison. This subset will review the evidence online over a set period and be able to make a recommendation outside of a full committee meeting. This will not alter standard governance or appeal processes and maintains the independence of the committee as a decision-making body.
06 September 2022 - 04 October 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 July 2022 In progress
22 March 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual